(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Two main forms of declining motor performance are evident in Parkinson's disease: response fluctuations and "loss of benefit", i.e., the progression of the disease without "on-off" symptoms. (-)Deprenyl has a favourable beneficial effect in reducing the mild forms of response fluctuations. The addition of (-)deprenyl in such patients to the continuing substitution therapy prevents the development of more severe "on-off" manifestations. In severely disabled patients with irregular response swings or permanent akinesia the use of (-)deprenyl as an adjuvant drug cannot modify anymore the course of the disease.
D001545:Benserazide / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D009069:Movement Disorders / Q000188:drug therapy*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*
D004338:Drug Combinations; D006834:Hydrazines; D010627:Phenethylamines; C005177:benserazide, levodopa drug combination; D012642:Selegiline; D007980:Levodopa; D001545:Benserazide